Asset profile
HM15211
Peptide
Evidence outlook · lead readout
NCT03374241 · Obesity
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03374241: The study was randomized, blinded and placebo-controlled, a solid safety-study design, but its only primary measure was a count of adverse events rather than a clinical or weight-related efficacy outcome, and no statistical test was applied to those counts.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.